Vote for BJP in urban local bodies" poll for "triple engine" govt in UP: Adityanath
UP: Man booked for attempting to rape 5-year-old girl
Congress to mark 100 days of Bharat Jodo Yatra with concert in Jaipur
BJYM, Hindu outfits put off planned protest march at AMU
Karachi battles gas crisis; residents face unannounced load shedding, 2-hr gas supply in a day
Elderly man in judicial custody dies during treatment in UP hospital
Himachal Pradesh skittle Haryana for 46, take 200-run lead on Day 1
Pak court grants protective bail to PM Shehbaz"s son Suleman in money laundering case
British Library celebrates India ties with exhibition on Hampi
Nine policemen suspended after suspect dies in police custody in UP
Gangster"s property attached in UP"s Pratapgarh district
Maoists torch construction company vehicles in Jharkhand’s Chatra district
Sino-India border situation "generally stable": China on Yangtse clash
Babar Azam not taking advice from seniors, claims Shahid Afridi
Qlite Global launches their exclusive Grand Experience Centre
"Disillusioned with central leadership": Sikkim BJP president says he has resigned
2001 attack anniversary: Ready to guard new Parliament if directed, say CRPF heroes
Class 2 student dies after scuffle with fellow students in UP
Three killed in accident in UP"s Lakhimpur KheriLakhimpur Kheri (UP), Dec 13 (PTI) Three motorcycle borne youths were killed and "
Abandoned girl child from Assam adopted by Spanish professor
Bharat Biotech, developing vaccines for infectious diseases, announced the first interim analysis of its BBV152 (Covaxin), on Wednesday. The whole virion inactivated COVID-19 vaccine candidate demonstrated an interim vaccine efficacy of 81 per cent in its phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with the Indian Council of Medical Research.
Interim Phase 3 Results: 81% Efficacy
The phase 3 study enrolled 25,800 participants between 18-98 years of age, including 2,433 over the age of 60 and 4,500 with comorbidities. The primary endpoint of phase 3 clinical trial is based on the first occurrence of PCR-confirmed symptomatic (mild, moderate, or severe) COVID-19 with onset at least 14 days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline.
The first interim analysis is based on 43 cases, of which 36 cases of COVID-19 were observed in the placebo group versus seven cases observed in the BBV152 (Covaxin) group, resulting in a point estimate of vaccine efficacy of 80.6 per cent.
The interim analysis included a preliminary review of the safety database, which showed that severe, serious, and medically attended adverse events occurred at low levels and were balanced between vaccine and placebo groups. The trial`s conduct and monitoring are as per good clinical practice guidelines and have been outsourced to IQVIA.
Analysis from the National Institute of Virology indicates that vaccine-induced antibodies can neutralise the UK variant strains and other heterologous strains, which has been published in bioRxiv.
Bharat Biotech expects to share further details of the trial results as additional data become available. Additional interim analysis is planned for 87 cases, and the final analysis is planned for 130 cases. All data from the second interim and final analyses will be shared via pre-publication servers as well as submitted to a peer-reviewed journal for publication.
Your support to NYOOOZ will help us to continue create and publish news for and from smaller cities, which also need equal voice as much as citizens living in bigger cities have through mainstream media organizations.
